Main Products / Services / Pipelines & Platforms
ON101is a topical macrophage regulator, a clinical breakthrough new drug for chronic wounds. With new drug approval in Taiwan, China, Macau, Singapore and Malaysia, and FDA’s fast track designation, ON101 is a game changer in chronic wound healing and will impact millions of lives.
FB825is a first-in-class anti-IgE B cell monoclonal antibody for allergic diseases, such as atopic dermatitis. Its novel mechanism of targeting and inhibiting the source of IgE enables its potential in disease modification to deliver dosing advantage and better safety. FB825 has been out-licensed to LEO Pharma since 2020.
FB704Ais a monoclonal antibody targeting the validated IL-6 pathway with best-in-class anti-inflammatory properties and well-supported safety profile. It is in Phase 2 clinical trial for severe asthma.
SNS812 is a siRNA new drug targeting a broad-spectrum of SARS-CoV-2 variants. It can tackle any future emerging wave and flu-like existence of coronaviruses. SNS812 is under a Phase 2 clinical trial in the US and in Taiwan.
Business Interests
Seeking out-licensing and collaborative R&D opportunities for first-in-class drugs based on innovative proprietary technology.
Contact Info
Zoe Chen
Director/ Business Development and Licensing
zoe.chen@onenessbio.com.tw